Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab

Pearse A Keane1, Srinivas R Sadda21NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 2Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USAAbstract: Re...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Keane PA, Sadda SR
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/1c41e548a2294cf9bff89a21cab9492a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1c41e548a2294cf9bff89a21cab9492a
record_format dspace
spelling oai:doaj.org-article:1c41e548a2294cf9bff89a21cab9492a2021-12-02T03:35:01ZRetinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab1177-54671177-5483https://doaj.org/article/1c41e548a2294cf9bff89a21cab9492a2011-06-01T00:00:00Zhttp://www.dovepress.com/retinal-vein-occlusion-and-macular-edema-ndash-critical-evaluation-of--a7623https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Pearse A Keane1, Srinivas R Sadda21NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 2Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USAAbstract: Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis®, Genentech, South San Francisco, CA) and bevacizumab (Avastin®, Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a result, ranibizumab has recently been approved by the US Food and Drug Administration for the treatment of RVO-associated macular edema. In this review, we provide a critical evaluation of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues in the management of this disorder. Keywords: ranibizumab, retinal vein occlusion, vascular endothelial growth factor, macular edemaKeane PASadda SRDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 771-781 (2011)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Keane PA
Sadda SR
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
description Pearse A Keane1, Srinivas R Sadda21NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 2Doheny Eye Institute, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USAAbstract: Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis®, Genentech, South San Francisco, CA) and bevacizumab (Avastin®, Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a result, ranibizumab has recently been approved by the US Food and Drug Administration for the treatment of RVO-associated macular edema. In this review, we provide a critical evaluation of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues in the management of this disorder. Keywords: ranibizumab, retinal vein occlusion, vascular endothelial growth factor, macular edema
format article
author Keane PA
Sadda SR
author_facet Keane PA
Sadda SR
author_sort Keane PA
title Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_short Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_full Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_fullStr Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_full_unstemmed Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_sort retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/1c41e548a2294cf9bff89a21cab9492a
work_keys_str_mv AT keanepa retinalveinocclusionandmacularedemaampndashcriticalevaluationoftheclinicalvalueofranibizumab
AT saddasr retinalveinocclusionandmacularedemaampndashcriticalevaluationoftheclinicalvalueofranibizumab
_version_ 1718401716575010816

Ejemplares similares